Can a Nurse Practitioner Prescribe GLP-1?
Everything you need to know about nurse practitioners prescribing GLP-1 medications like semaglutide and tirzepatide. Learn about NP prescribing authority, state variations, and how NP-led care works for weight management.
More on Provider & Access
The Short Answer: Yes
Nurse practitioners (NPs) are fully qualified and legally authorized to prescribe GLP-1 medications including semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound), and other weight management medications. NPs are advanced practice registered nurses (APRNs) with master's or doctoral degrees who complete specialized training in diagnosing conditions, developing treatment plans, and prescribing medications.
In fact, NPs represent a significant and growing portion of GLP-1 prescribers. As demand for obesity medicine services has surged far beyond the supply of board-certified obesity medicine physicians, NPs have stepped in to fill a critical access gap. Many telehealth GLP-1 platforms rely primarily on NP prescribers to serve their patient populations.
Understanding NP Prescribing Authority
Full Practice Authority (27+ States)
NPs evaluate, diagnose, and prescribe independently without physician oversight. States include California, New York, Colorado, Oregon, Washington, Arizona, and many others. This is the national trend, with more states adopting full practice authority each year.
Reduced Practice Authority
NPs must have a collaborative agreement with a physician but can prescribe independently within that agreement. The physician does not need to see every patient or co-sign every prescription. States include Pennsylvania, Ohio, and Indiana.
Restricted Practice Authority
NPs require direct physician supervision for some or all prescribing activities. States include Texas, Florida, and Georgia. Even in these states, NPs routinely prescribe GLP-1 medications with appropriate physician collaboration in place.
What to Expect from NP-Led GLP-1 Care
NP-led weight management follows the same evidence-based protocols as physician-led care:
- Comprehensive evaluation: Medical history, BMI assessment, contraindication screening, and treatment goal discussion
- Lab ordering: Baseline and monitoring blood work through the same lab networks
- Medication selection: Evidence-based choice between semaglutide, tirzepatide, or other options based on your clinical profile
- Titration management: Careful dose escalation with monitoring for side effects
- Ongoing monitoring: Regular check-ins, lab review, and dose adjustments
- Referrals when needed: NPs refer to specialists (endocrinology, cardiology, etc.) when clinical situations warrant expert consultation
Learn more about how GLP-1 treatment works regardless of provider type.
Why NPs Are Critical for GLP-1 Access
There are approximately 355,000 practicing NPs in the US compared to fewer than 5,000 board-certified obesity medicine physicians. With over 100 million American adults living with obesity, NPs are essential for meeting the demand for evidence-based weight management. Without NP prescribers, most patients would face months-long wait times or be unable to access GLP-1 therapy at all.
NPs in obesity medicine often develop deep expertise through years of focused practice, continuing education, and patient volume that rivals or exceeds many general physicians. Specialization matters more than degree type when it comes to quality of care.
Medical Disclaimer: This article is for educational purposes only. Prescribing authority varies by state and is subject to change. Verify your provider's credentials and licensing status before beginning treatment.
Frequently Asked Questions
Can a nurse practitioner prescribe Wegovy or Ozempic?
Yes, nurse practitioners can prescribe GLP-1 medications including Wegovy, Ozempic, Mounjaro, and Zepbound. In states with full practice authority, NPs prescribe independently. In states with reduced or restricted authority, NPs may need a collaborative agreement with a physician. The clinical evaluation, prescribing, and monitoring process is the same regardless of provider type.
Is care from a nurse practitioner as good as from a doctor for GLP-1?
Research consistently shows that NP-provided care produces equivalent patient outcomes to physician-provided care across many conditions including chronic disease management. For GLP-1 prescribing, both NPs and physicians follow the same clinical guidelines, order the same labs, and manage the same titration protocols. Patient satisfaction with NP care is often equal to or higher than physician care.
Do all states allow nurse practitioners to prescribe GLP-1?
All states allow NPs to prescribe medications including GLP-1s, but the level of independence varies. Approximately 27 states plus DC grant full practice authority, meaning NPs prescribe independently. Other states require varying levels of physician oversight. Your NP will operate within the regulations of the state where you receive care.
Can a nurse practitioner prescribe GLP-1 through telehealth?
Yes, NPs can prescribe GLP-1 medications through telehealth platforms. Many online GLP-1 providers employ nurse practitioners as their primary prescribers. The NP must be licensed in the state where the patient is located at the time of the consultation. Telehealth NP prescribing follows the same clinical standards as in-person care.
What training do nurse practitioners have for prescribing weight loss medications?
NPs complete master's or doctoral-level education that includes advanced pharmacology, pathophysiology, and clinical assessment. Many NPs specializing in weight management pursue additional certification through the American Board of Obesity Medicine or complete continuing education in metabolic medicine. Their pharmacology training is specifically designed for independent prescribing responsibility.
Connect with a Licensed GLP-1 Provider
Our clinical team includes experienced NPs and physicians specializing in weight management.
Get Started TodaySources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).